Consortium outlines clearer path to value-based drug pricing

The Robert J. Margolis Center for Health Policy at Duke University and a public-private consortium released a report outlining recommendations to overcome legal and regulatory barriers to value-based payment arrangements for medical products, including steps to clarify guidance around the U.S. anti-kickback statute and Medicaid best price rules.

A consortium comprising patient advocates, payers, manufacturers and policy experts formed by the Duke-Margolis Center said hurdles to value-based pricing involve current U.S. laws and regulations designed to address appropriate concerns about overuse, misuse, and excess spending within fee-for-service payment systems. However, these regulations can complicate and sometimes prevent adoption of new pricing models. ...